ClinicalTrials.gov
ClinicalTrials.gov Menu

Continuous Monitoring of Prostate Position During Radiotherapy (KIM Gating)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01742403
Recruitment Status : Recruiting
First Posted : December 5, 2012
Last Update Posted : April 5, 2018
Sponsor:
Information provided by (Responsible Party):
Associate Professor Thomas Eade, Royal North Shore Hospital

Brief Summary:
This study is investigating measurement of prostate motion during radiotherapy using the implanted gold markers. If motion is greater than 3mm then the beam will be stopped and position corrected (gating).

Condition or disease Intervention/treatment Phase
Prostate Cancer Radiation: R/T gating kV intrafraction monitoring Not Applicable

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Feasibility Study of Prostate Cancer Radiotherapy Gating Using kV Intrafraction Monitoring (KIM)
Study Start Date : January 2013
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : June 2019

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: R/T gating kV intrafraction monitoring

Intervention: Recruitment will be performed in 2 phases:

Phase I will include the first 10 patients. All patients will be treated on a standard fractionation protocol with 40 fractions. This will allow 400 potential fractions to be auto-segmented in real time. Once Phase I is successfully completed we will aim to continue recruitment of a further 20 patients as Phase II. For this phase we will open recruitment to patients with lymph node positivity, hypofractionation (as per Department protocols) and intermittent imaging (imaging less frequently than every fraction).

Radiation: R/T gating kV intrafraction monitoring
This is a Phase I Pilot study to assess the feasibility of implementing prostate radiotherapy gating using kV intrafraction monitoring.



Primary Outcome Measures :
  1. Feasibility [ Time Frame: 2 years ]
    Technique will be determined as feasible if 90% of treatment fractions are successfully segmented in real time.


Secondary Outcome Measures :
  1. Time for procedure [ Time Frame: 2 years ]
    Measurement of time taken to perform KIM gating to guide future department resource questions.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients undergoing definitive external beam radiotherapy;
  • Histological proven prostate adenocarcinoma
  • Prostate Specific Antigen (PSA),within 3 months prior to enrolment
  • Patient must be able to have gold fiducial markers placed in the prostate (if on anticoagulants, must be approved for procedure by Cardiologist)
  • Artificial hips
  • Lymph Node irradiation
  • Patient Dimensions >40cms
  • ECOG 0-2
  • Ability to understand and willingness to sign informed consent form.

Exclusion Criteria:

  • Altered fractionation
  • Fiducials must be no less than 1cm apart

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01742403


Contacts
Contact: Thomas N Eade, MBBS +61294631319 TEade@nsccahs.health.nsw.gov.au
Contact: Jeremy Booth, PhD +61294631320 JBooth@nsccahs.health.nsw.gov.au

Locations
Australia, New South Wales
Department of Radiation Oncology, Northern Sydney Cancer Centre Recruiting
St. Leonards, New South Wales, Australia, 2065
Contact: Thomas N Eade, MBBS    +61294631315    Thomas.Eade@health.nsw.gov.au   
Contact: Clare Banks, MPH    +61 2 9463 1345    Clare.Banks@health.nsw.gov.au   
Principal Investigator: Thomas N Eade, RANZCR I & II         
Sponsors and Collaborators
Royal North Shore Hospital
Investigators
Principal Investigator: Thomas Eade, MBBS Royal North Shore Hospital

Publications of Results:
Responsible Party: Associate Professor Thomas Eade, Radiation Oncologist, Royal North Shore Hospital
ClinicalTrials.gov Identifier: NCT01742403     History of Changes
Other Study ID Numbers: 12-NSCCRO-P001
First Posted: December 5, 2012    Key Record Dates
Last Update Posted: April 5, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: With other ethics approved centres using annonymised data.

Keywords provided by Associate Professor Thomas Eade, Royal North Shore Hospital:
Prostate
IGRT
VMAT

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases